• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Azenta to Participate in the Baird 2022 Global Healthcare Conference

    9/6/22 4:05:00 PM ET
    $AZTA
    $BRKS
    Industrial Machinery/Components
    Technology
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    CHELMSFORD, Mass., Sept. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Baird 2022 Global Healthcare Conference in New York City, on Wednesday, September 14, 2022, which includes a presentation beginning at 9:40 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.

    About Azenta Life Sciences

    Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (NASDAQ:AZTA) from Brooks Automation, Inc, (NASDAQ:BRKS).

    Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

    INVESTOR CONTACTS:

    Sara Silverman

    Head of Investor Relations

    978.262.2635

    [email protected]

    Sherry Dinsmore

    978.262.2400

    [email protected] 

    Azenta logo (PRNewsfoto/Azenta)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-to-participate-in-the-baird-2022-global-healthcare-conference-301618601.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA
    $BRKS

    CompanyDatePrice TargetRatingAnalyst
    Azenta Inc.
    $AZTA
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    Azenta Inc.
    $AZTA
    4/4/2024$64.00Hold
    Jefferies
    Azenta Inc.
    $AZTA
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    Azenta Inc.
    $AZTA
    7/19/2023Mkt Perform
    Raymond James
    Azenta Inc.
    $AZTA
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    Azenta Inc.
    $AZTA
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    Azenta Inc.
    $AZTA
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    Azenta Inc.
    $AZTA
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    $BRKS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development

      Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy development through a fully integrated sequencing and data analysis solution. This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy wi

      5/13/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    $BRKS
    SEC Filings

    See more
    • SEC Form SD filed by Azenta Inc.

      SD - Azenta, Inc. (0000933974) (Filer)

      5/30/25 4:15:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/16/25 4:12:24 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      5/9/25 4:07:49 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    $BRKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Azenta upgraded by Stephens with a new price target

      Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

      12/18/24 7:25:24 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Jefferies initiated coverage on Azenta with a new price target

      Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00

      4/4/24 7:29:19 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • B. Riley Securities reiterated coverage on Azenta with a new price target

      B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously

      2/1/24 8:17:35 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    $BRKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Marotta John was granted 1,000 units of Common, increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      6/4/25 4:30:06 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: President and CEO Marotta John was granted 5,434 units of Common, increasing direct ownership by 5% to 106,296 units (SEC Form 4)

      4/A - Azenta, Inc. (0000933974) (Issuer)

      6/4/25 4:10:08 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 12,000 units of Common, increasing direct ownership by 238% to 17,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      6/3/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology